Multiple Sclerosis Experiment

1451 Words3 Pages

Cody Munoz The human body is amazingly physically capable and is able to create a number of complex movements and generate varying amounts of force, with varying speed and control of the movement due to the function of the body’s Central Nervous System. The Central Nervous System transmits messages from the brain to the part of the body a person wishes to move by using nerve fibers very rapidly, and this results in humans being able to complete a number of complex movements in very controlled manners and at considerably fast paces. However, sometimes the transmission of messages from the brain to the Spinal Cord can become disrupted, and this leads to less control of movements and can lead to movements becoming slowed down or even stopped …show more content…

This trial looked at improvements in a timed 25-foot walk and had an evaluator examine the improvement of each individual’s hip flexor strength, knee flexor and extensor strength, and ankle dorsiflexor strength. Like the test in the previous trial, these tests were designed to investigate improvement in muscle coordination and function, both of which generally decrease for those afflicted with Multiple Sclerosis. In the study, one group took a placebo sugar pill while the other group took 10mg of Fampridine-SR twice daily for 9 weeks. 119 participants received the 10mg of Fampridine-SR, and 118 received the placebo sugar pill. The results showed that there were 51 responders to the Fampridine-SR group, and 11 responders to the placebo group. This is very significant and indicates that Fampridine-SR could be very useful for treating symptoms of Multiple Sclerosis. The results also showed a somewhat significant difference in the evaluator tests. For the Fampridine-SR regiment, results showed a difference of .09 and the placebo group showed a difference of .04 based on the evaluator scale, which was designated to have a minimum of 0 and a maximum of 5. This shows Fampridine-SR could be effective in treating both the primary and secondary outcomes measured during this trial. There were adverse events in 5% of the Fampridine-SR participants and 3.36 % of the placebo group. This is a very insignificant difference when compared to the placebo group so there is not too much concern about these events and the results didn’t indicate there was any safety issue. The results of both of these clinical trials show that Fampridine-SR can be effective in treating symptoms of Multiple Sclerosis, specifically

More about Multiple Sclerosis Experiment

Open Document